Patents Assigned to ASTECH. CO., LTD.
  • Patent number: 11712414
    Abstract: Disclosed is an oral pharmaceutical composition for preventing or treating dry eye syndrome, which comprises rebamipide or a prodrug thereof, or a pharmaceutically acceptable salt thereof, as an active ingredient. The compounds can treat dry eye syndrome via oral route, and can be thus employed safely and conveniently compared to conventional eye drops.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: August 1, 2023
    Assignees: SAMJIN PHARMACEUTICAL CO., LTD., ASTECH. CO., LTD.
    Inventors: Eui Hwan Cho, Sung Ju Choi, Sung Woo Lee, Hee Jong Shin, Jong Bae Yoon, Ki Seok Park, Ho Tae Nam
  • Patent number: 11420963
    Abstract: Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: August 23, 2022
    Assignees: SAMJIN PHARMACEUTICAL CO., LTD., ASTECH. CO., LTD.
    Inventors: Eui Hwan Cho, Sung Ju Choi, Sung Woo Lee, Hee Jong Shin, Ho Seok Kwon, Jae Woong Lee, Jeong Ho Joo, Hyun Tae Kim, Woo Heon Song, Jong Bae Yoon, Ki Seok Park, Ho Joon Park, Ho Tae Nam
  • Publication number: 20140154330
    Abstract: Disclosed are spherical particles of clopidogrel bisulfate and a pharmaceutical composition containing the same. The spherical particles can be used for preparing a tablet having sufficient hardness through direct compression, by improving unformulable properties of clopidogrel bisulfate such as compressibility, flowability and strong surface electrostatic charges, reduce a problem in compressing tablets such as weight variation, sticking, etc., and the risk of form conversion, and improve physiochemical stability. Therefore, the spherical particles of the present invention may be used as therapeutics for arteriosclerosis, stroke, myocardial infarction and atherosclerosis.
    Type: Application
    Filed: October 27, 2011
    Publication date: June 5, 2014
    Applicants: ASTECH. CO., LTD., SAMJIN PHARMACEUTICAL CO., LTD.
    Inventors: Eui Hwan Cho, Hee Jong Shin, Woo Heon Song, Sun Hwan Lee, Jong Bae Yoon, Jong Sung Park